Loading
Cancer, Stress, Anesthesia, and Immune Response / Cancer Research and Treatments · Journal article
Nature Communications · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a proof-of-concept study demonstrating that engineered attenuated Salmonella typhimurium, engineered to express PTEN and deliver an MDM2 inhibitor on nanoparticles, achieves substantial tumor inhibition and survival benefit in murine melanoma. The approach is novel and mechanistically sound but remains entirely preclinical; safety, immunogenicity, and efficacy in humans are unknown.
Preclinical murine tumor model study. Murine melanoma models; specific strain, age, sex, immune status, and cohort sizes not stated.. Intervention: Engineered attenuated Salmonella typhimurium VNP20009 with quorum-sensing-regulated PTEN expression and surface-conjugated nanoparticles delivering MDM2 inhibitor, optionally combined with anti-PD-1 therapy.. Compared with: Not explicitly stated in abstract..
94.9% tumor inhibition achieved in murine melanoma Durable survival in all treated mice when combined with anti-PD-1 therapy Engineered bacteria function as exogenous organelle mimics providing continuous PTEN supplementation
No human subjects or clinical data; murine model may not predict human safety or efficacy. Long-term toxicity, immunogenicity, and biodistribution in mammals not detailed.
This preclinical finding suggests potential for engineered bacterial therapy as a platform to restore multiple tumor suppressors simultaneously, but clinical translation requires rigorous safety and efficacy assessment. The approach is at an exploratory stage and should not inform clinical practice decisions.
This is a proof-of-concept study in murine melanoma using a novel engineered bacterial platform with surrogate endpoints; efficacy and safety in humans remain untested.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding suggests potential for engineered bacterial therapy as a platform to restore multiple tumor suppressors simultaneously, but clinical translation requires rigorous safety and efficacy assessment. The approach is at an exploratory stage and should not inform clinical practice decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
PTEN and p53 are two pivotal tumor suppressors that synergistically restrain tumor progression but are frequently inactivated in cancer. Restoring their functions is a promising therapeutic strategy but remains limited by unsustainable protein production and off-target effects. Here, we report a biohybrid platform integrating engineered attenuated Salmonella typhimurium VNP20009 with nanotechnology to enable durable restoration of PTEN and p53 functions in tumors. The bacteria are engineered with a quorum-sensing-regulated lysis circuit coupled to PTEN expression, enabling controlled proliferation and sustained PTEN production and release. Their intrinsic tumor tropism and long-term intracellular parasitism allow them to function as exogenous organelle mimics, providing continuous PTEN supplementation. Surface-conjugated nanoparticles further deliver the MDM2 inhibitor to stabilize p53 and synergistically restore the PTEN-p53 network. This platform achieves 94.9% tumor inhibition in murine melanoma and confers durable survival in all treated mice when combined with anti-PD-1 therapy, highlighting its strong therapeutic potential for cancer treatment. PTEN and p53 are two of the most frequently mutated or inactivated tumor suppressor genes. Here, the authors engineer Salmonella to act as exogenous organelle-like devices that deliver PTEN and an MDM2 inhibitor to reactivate p53 to tumors, achieving durable tumor suppression and synergistic immune activation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.